These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 30112718)

  • 1. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.
    Chanthawong S; Lim YH; Subongkot S; Chan A; Andalusia R; Ahmad Bustamam RS; Chaiyakunapruk N
    Support Care Cancer; 2019 Mar; 27(3):1109-1119. PubMed ID: 30112718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.
    Yokoe T; Hayashida T; Nagayama A; Nakashoji A; Maeda H; Seki T; Takahashi M; Takano T; Abe T; Kitagawa Y
    Oncologist; 2019 Jun; 24(6):e347-e357. PubMed ID: 30333194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong.
    Chan SL; Jen J; Burke T; Pellissier J
    Asia Pac J Clin Oncol; 2014 Mar; 10(1):80-91. PubMed ID: 24571059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of aprepitant for patients who truly need it in Japan.
    Tsukiyama I; Ando M; Tsukiyama S; Takeuchi M; Ejiri M; Kurose Y; Saito H; Arakawa I; Inoue T; Yamaguchi E; Kubo A
    Support Care Cancer; 2019 Oct; 27(10):3749-3758. PubMed ID: 30710243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2019 May; 41(5):929-942. PubMed ID: 31036286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
    Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
    Moore S; Tumeh J; Wojtanowski S; Flowers C
    Value Health; 2007; 10(1):23-31. PubMed ID: 17261113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.
    Chow R; Chiu L; Herrstedt J; Aapro M; Lock M; DeAngelis C; Navari RM
    Support Care Cancer; 2021 Aug; 29(8):4269-4275. PubMed ID: 33409724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan.
    Kashiwa M; Matsushita R
    BMC Health Serv Res; 2019 Jul; 19(1):438. PubMed ID: 31262292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
    Gao J; Zhao J; Jiang C; Chen F; Zhao L; Jiang Y; Li H; Wang W; Wu Y; Jin Y; Da L; Liu G; Zhang Y; Li H; Zhang Z; Jin G; Li Q
    Support Care Cancer; 2022 Jul; 30(7):6225-6232. PubMed ID: 35449368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine cost-effectiveness in vomiting and nausea from highly emetogenic chemotherapy in children and adolescents.
    Sra MS; Ganguly S; Naik RD; Sasi A; Sharma P; Giri RK; Abdul Rasheed A; Bakhshi S
    BMJ Support Palliat Care; 2024 Jan; 13(e3):e1272-e1279. PubMed ID: 36813535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
    Botteman M; Nickel K; Corman S; Turini M; Binder G
    Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.
    Iihara H; Shimokawa M; Abe M; Hayasaki Y; Fujita Y; Nagasawa Y; Sakurai M; Matsuoka R; Suzuki A; Morishige K
    BMJ Open; 2019 Jan; 9(1):e024357. PubMed ID: 30782732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium.
    Annemans L; Strens D; Lox E; Petit C; Malonne H
    Support Care Cancer; 2008 Aug; 16(8):905-15. PubMed ID: 17965891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia.
    Keat CH; Ghani NA
    Asian Pac J Cancer Prev; 2013; 14(12):7701-6. PubMed ID: 24460356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
    Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.
    Slimano F; Netzer F; Borget I; Lemare F; Besse B
    Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
    Yeo W; Lau TK; Li L; Lai KT; Pang E; Cheung M; Chan VT; Wong A; Soo WM; Yeung VT; Tse T; Lam DC; Yeung EW; Ng KP; Tang NL; Tong M; Suen JJ; Mo FK
    Breast; 2020 Apr; 50():30-38. PubMed ID: 31978815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.